Norges Bank Acquires New Shares in Prestige Consumer Healthcare Inc. $PBH

Norges Bank acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 599,024 shares of the company’s stock, valued at approximately $36,954,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP lifted its holdings in Prestige Consumer Healthcare by 4.8% in the third quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company’s stock valued at $161,723,000 after acquiring an additional 119,459 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Prestige Consumer Healthcare by 1.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,613,460 shares of the company’s stock worth $98,776,000 after buying an additional 21,085 shares during the period. Bank of America Corp DE increased its position in shares of Prestige Consumer Healthcare by 19.1% during the second quarter. Bank of America Corp DE now owns 721,371 shares of the company’s stock valued at $57,601,000 after acquiring an additional 115,459 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Prestige Consumer Healthcare by 10.2% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company’s stock valued at $40,147,000 after acquiring an additional 60,496 shares during the last quarter. Finally, Raymond James Financial Inc. raised its stake in shares of Prestige Consumer Healthcare by 15.7% in the 3rd quarter. Raymond James Financial Inc. now owns 637,932 shares of the company’s stock valued at $39,807,000 after acquiring an additional 86,373 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of the company’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the sale, the vice president owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Stock Up 1.1%

Shares of PBH opened at $47.69 on Tuesday. The stock has a market capitalization of $2.26 billion, a PE ratio of 12.20, a P/E/G ratio of 1.52 and a beta of 0.35. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $87.12. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.25 and a current ratio of 3.57. The company’s 50-day simple moving average is $52.82 and its 200-day simple moving average is $59.89.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.39 by ($0.16). The business had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The firm’s revenue for the quarter was down 5.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Analysts forecast that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on PBH shares. Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Zacks Research downgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a research note on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Hold” and a consensus target price of $70.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).